ストックスクリーナーアプリを入手
1.40
2.94%
0.04
アフターアワーズ：
1.35
-0.05
-3.57%
前日終値:
$1.36
開ける：
$1.37
24時間の取引高:
44,042
Relative Volume:
0.50
時価総額：
$20.00M
収益：
$48,200
当期純損益:
$-16.66M
株価収益率:
-0.7852
EPS:
-1.783
ネットキャッシュフロー:
$-17.15M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-18.60%
6か月 パフォーマンス:
-32.69%
1年 パフォーマンス:
-51.42%
1日の値動き範囲:
$1.37
$1.4244
1週間の範囲:
$1.27
$1.4244
52週間の値動き範囲:
$1.27
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Compare DARE vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.40 | 19.43M | 48,200 | -16.66M | -17.15M | -1.783 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Dare Bioscience Inc (DARE) 最新ニュース
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Dare Bioscience Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
A Viagra ingredient is now in a topical cream developed for women - Stock Titan
Dare Bioscience (DARE) Expected to Announce Earnings on Monday - Defense World
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 - The Manila Times
Daré Bioscience, Inc. to Host Conference Call on March 26, 2026, for Year-End Financial Results and Company Update - Quiver Quantitative
Daré Bioscience schedules March 26 webcast for 2025 results - Stock Titan
DARE BIOSCIENCE, INC. Files Form 8-K with SEC Reporting Unregistered Sale of Equity Securities - Minichart
Dare Bioscience secures NIH funding extension for preterm birth therapy - MSN
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks
Daré Bioscience (DARE) issues 43,050 preferred-and-warrant units - Stock Titan
Daré Bioscience extends NIH grant period for preterm birth drug By Investing.com - Investing.com Australia
DARE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dare Bioscience (DARE) Advances Investigational Preterm Birth Tr - GuruFocus
Dare Bioscience receives NIH funding extension for preterm birth treatment By Investing.com - Investing.com Australia
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - The Manila Times
NIH funds hormone ring as preterm birth lacks FDA-approved treatment - Stock Titan
Daré Bioscience Participates in Virtual Investor “What This Means” Segment - Sahm
Dare Bioscience Participates in Virtual Investor "What This Means" Segment - Bitget
Persistent HPV has no FDA-approved drug; Daré CEO lays out DARE-HPV trial plan - Stock Titan
Daré Bioscience Participates in Virtual Investor 'What This Means” Segment - The Manila Times
Daré Bioscience Completes Second Closing of Regulation A Offering - TipRanks
Daré Bioscience (NASDAQ: DARE) advances Regulation A unit offering - Stock Titan
Daré Bioscience Updates Investor Presentation Under Regulation FD - TipRanks
Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K - Stock Titan
DARE Should I Buy - Intellectia AI
DARE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Daré Bioscience gets FDA clearance for HPV treatment trial By Investing.com - Investing.com India
Daré Bioscience gets FDA clearance for HPV treatment trial - Investing.com Australia
Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Bitget
Daré Bioscience Announces FDA Clearance of IND for Phase 2 - GlobeNewswire
Dare Bioscience (DARE) CEO subscribes to Reg A units with warrants - Stock Titan
DARE SEC FilingsDare Bioscience Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dare Bioscience Launches Telehealth Consultations for Women's Arousal Cream - Intellectia AI
Dare Bioscience (DARE) Launches Telehealth for Topical Sildenafi - GuruFocus
First-of-its-kind arousal cream for women offers US-wide telehealth access - Stock Titan
Telehealth Now Available for DARE to PLAY™ Sildenafil - GlobeNewswire
Dare Bioscience Secures Strategic Autonomy with Key Asset Reversion - AD HOC NEWS
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Dare Bioscience launches preferred stock and warrant offering on Nasdaq - Investing.com
Daré Bioscience Launches Regulation A Preferred Unit Offering - TipRanks
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth - Yahoo Finance
Dare Bioscience (NASDAQ:DARE) Share Price Passes Below 50-Day Moving Average – What’s Next? - Defense World
Daré Bioscience issues updated investor corporate presentation - MSN
Daré Bioscience Issues Updated Investor Corporate Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Dare Bioscience Earnings Notes - Trefis
Dare Bioscience Inc (DARE) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):